A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 12 lat i waga co najmniej 40 kg
- •Ogólny stan zdrowia pacjenta pozwalający na leczenie
- •Białaczka powracająca lub oporna na poprzednie leczenie z określonymi mutacjami genetycznymi
- •Liczba białych krwinek poniżej 25 000 na mikroliter krwi
- •Prawidłowa funkcja serca (frakcja wyrzutowa powyżej 40%)
- •Prawidłowa funkcja wątroby
- •Prawidłowa funkcja nerek
- •Zgoda pacjenta lub opiekuna na uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- September 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Memorial Sloan Kettering Cancer Center
New York, United States
MD Anderson Cancer Center
Houston, United States
Trial contact
Ghayas Issa, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.